What it sells
Your biopharma team, from molecule design to portfolio strategy
Business model breakdown
Buyer: who owns the budget?
UnverifiedR&D, BD or portfolio heads at biotech and pharma
Trigger: what makes them buy now?
A discovery, development, licensing or portfolio decision needing research, analysis and modeling quickly
Workflow: what inputs become what output?
Discuss a project, approve scope, Quinn researches, analyzes data, builds models and designs molecules/studies, delivers a report with underlying work in 3-5 days
Economics: what it saves and how it charges
UnverifiedProject-based engagement per deliverable; price not shown
Distribution: how it reaches customers
Inbound Discuss a project, consultative; SOC 2 Type II, ISO 27001, HIPAA BAA available
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2022 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.